Sheet 1 of 1 FOR PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO .: **APPLICATION NO.:** PATENT AND TRADEMARK OFFICE CN01383K 10/072,340 INFORMATION DISCLOSURE STATEMENT APPLICANT: John A. Hey, et al. BY APPLICANT FILING DATE: GROUP: (Use several sheets if necessary) 2/6/2002 1617 U.S. PATENT DOCUMENTS EXAMINER DOCUMENT DATE NAME CLASS SUB-FILING DATE IF INITIAL NUMBER CLASS **APPROPRIATE** BA 2,624,734 m 1/6/1953 Moses Wolf Goldberg et al. BB BC BD BE BF BG 2 y 2003 ВН BI TECH CENTER 1600/2900 BJ BK

FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUB-TRANSLATION NUMBER CLASS YES NO BL ВМ BN BO BP OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) BQ Craig D. Boyle et al., Bioorganic & Medicinal Chemistry Letters, 10 pp. 2727-2730 (2000) Stephen L. Yates et al., The Journal of Pharmacology & Experimental Therapeutics, 289 (2), pp.1151-1159 (1999) X. Ligneau et al., The Journal of Pharmacology & Experimental Therapeutics 287, (2) pp. 658-666 BS Rob Leurs et al., Elsevier Science Ltd., 19, pp. 177-184 (1998) BT Maria Grazia Giovannini et al., Behavioural Brain Research 104, pp. 147-155 (1999) BU Susan R. McGurk, Ph.D., J. Clin Psychiatry 60 (suppl 12), pp 24-29 (1999)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

Nita Nacasch et al., Clinical Neuropharmacology, 21, (2) pp. 132-134 (1998)

Folia Pharmacol. Jpn., 114, pp. 89-106 (1999) - XP008021117

BW

BX BY

m

**EXAMINER**